Oxytocin Administration Guidelines

Monitoring and Administration

The European Society of Cardiology recommends pulse oximetry and continuous ECG monitoring as clinically indicated for patients receiving oxytocin 1, 2
In patients with obstructive valve lesions, hypertrophic cardiomyopathy, or other structural heart disease, oxytocin must be given only as a slow infusion to avoid hypotension and tachycardia, as suggested by the European Heart Journal 3, 4
For high-risk cardiac patients, the European Heart Journal recommends administering oxytocin at rates less than 2 U/min (approximately 33 mU/min) to avoid systemic hypotension 1, 2, 6
Continuous hemodynamic monitoring should be maintained for at least 24 hours after delivery due to significant fluid shifts, as recommended by the European Heart Journal 1, 2

In patients with severe bronchiectasis, oxytocin may cause acute hypoxemia resistant to supplemental oxygen, possibly due to increased shunting through damaged lung, as reported in the European Respiratory Journal 5
Ergotamine should be avoided in patients with respiratory disease as it may cause bronchospasm, according to the European Respiratory Journal 5, 7

The European Heart Journal advises against administering oxytocin as a rapid IV bolus during labor, as this can cause severe hypotension, tachycardia, and uterine hyperstimulation 3, 4
Methylergonovine should be avoided in the postpartum period due to risk (>10%) of vasoconstriction and hypertension, as recommended by the European Heart Journal 1, 2, 6